Literature DB >> 25943491

The ups and downs of clinical translation of new technologies: déjà vu all over again.

Paul A Burke1.   

Abstract

Mesh：

Year:  2015        PMID： 25943491      PMCID： PMC4427882          DOI： 10.1038/mt.2015.51

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  5 in total

Review 1.  Aptamers: novel diagnostic and therapeutic tools for diabetes mellitus and metabolic diseases.

Authors:  Jingping Hu; Mao Ye; Zhiguang Zhou
Journal:  J Mol Med (Berl)       Date:  2016-11-15       Impact factor: 4.599

2.  The Toxicokinetic Profile of Dex40-GTMAC3-a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin.

Authors:  Emilia Sokolowska; Bartlomiej Kalaska; Kamil Kaminski; Alicja Lewandowska; Agnieszka Blazejczyk; Joanna Wietrzyk; Irena Kasacka; Krzysztof Szczubialka; Dariusz Pawlak; Maria Nowakowska; Andrzej Mogielnicki
Journal:  Front Pharmacol       Date:  2016-03-17       Impact factor: 5.810

3.  An in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin.

Authors:  Sylvain Ursuegui; Marion Recher; Wojciech Krężel; Alain Wagner
Journal:  Nat Commun       Date:  2017-05-19       Impact factor: 14.919

4.  A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers.

Authors:  Kazuhiko Haruta; Natsuki Otaki; Masakazu Nagamine; Tomoyoshi Kayo; Asako Sasaki; Shinsuke Hiramoto; Masayuki Takahashi; Kuniyoshi Hota; Hideaki Sato; Hiroaki Yamazaki
Journal:  Nucleic Acid Ther       Date:  2016-11-09       Impact factor: 5.486

Review 5.  The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.

Authors:  Beatriz G de la Torre; Fernando Albericio
Journal:  Molecules       Date:  2017-02-27       Impact factor: 4.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.